Abstract
As described in Chapter 1, the complement system comprises a battery of at least 20 components capable of immediate response to a foreign organism or cell, resulting in lysis or opsonization and phagocytosis. Uncontroled complement activation would result in damage to host tissues, or in extreme cases, consumption and effective depletion of complement components. Intrinsic to the complement cascade are multiple strategies for control, such as the inherent lability of the activation enzymes, the C3 and C5 convertases, and shortlived active/binding sites, such as the binding site on C5b67 for membranes. In addition to this inherent instability, complement activation is tightly controled at multiple stages during the pathway by regulatory proteins, present both on cell membranes and in plasma (1–4). The regulatory activities possessed by these proteins fall into four categories: (1) control of the active C1 complex; (2) “decay acceleration,” characterized by the ability of the regulator to “breakup” the components of the multimolecular convertase enzymes; (3) “cofactor activity,” enabling factor I to cleave and inactivate C3b or C4b; and finally, (4) inhibition of membrane attack complex (MAC) assembly. Some regulatory proteins have just one of these activities, others possess several.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pensky J., Levy L., and Lepow I. (1961) Partial purification of a serum inhibitor of C1′esterase. Biol. J. Chem. 236, 1674.
Whaley K. and Ruddy S. (1976) Modulation of the alternative complement pathways by beta 1 H globulin. J. Experiment. Med. 144, 1147.
Gigli I., Fujita T., and Nussenzweig V. (1979) Modulation of the classical pathway C3 convertase by the plasma proteins C4 binding protein and C3b inactivator. Proc. Natl. Acad. Sci. USA 76, 6596.
Morgan B. P. and Meri S. (1994) Membrane proteins that protect against complement lysis. Springer Semin. Immunopathol. 15, 369.
Weiler J. M., Daha M. R., Austen K. F., and Fearon D. T. (1976) Control of the amplification convertase of complement by the plasma protein beta1H. Proc. Natl Acad. Sci. USA 73, 3268.
Fearon D. T. (1979) Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membranes. Proc. Natl. Acad. Sci. USA 76, 5867.
Nicholson-Weller A., Burge J., and Fearon D. T. (1982) Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J. Immunol. 129, 184.
Medof M. E., Kinoshita T., and Nussenzweig V. (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J. Experiment. Med. 160, 1558.
Seya T., Holers V. M., and Atkinson J. P. (1985) Purification and functional analysis of the polymorphic variants of the C 3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF). J.Immunol. 135, 2661.
Brodbeck W. G., Liu D., Sperry J., Mold C., and Medof M. E. (1996) Localization of classical and alternative pathway regulatory activity within the decay accelerating factor. J. Immunol. 156, 2528.
Lublin D. M. and Coyne K. E. (1991) Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage. J.Experiment. Med. 174, 35.
Oglesby T. J., Allen C. J., Liszewski M. K., White D. J., and Atkinson J. P.(1992) Membrane cofactor protein (CD46) protects cells from complement mediated attack by an intrinsic mechanism. J. Experiment. Med. 175, 1547.
Whaley K. (1985) Measurement of complement, in Methods in Complement for Clinical Immunologists (Whaley K., ed.), Churchill Livingstone, Edinburgh, p. 77.
Fujita T. and Nussenzweig V. (1979) The role of C4-binding protein and beta 1H in proteolysis of C4b and C3b. J. Experiment. Med. 150, 267.
Yoon S. H. and Fearon D. T. (1985) Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma. J. Immunol. 134, 3332.
Seya T., Turner J. R., and Atkinson J. P. (1986) Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J. Experiment. Med. 163, 837.
Seya T. and Atkinson J. P. (1989) Functional properties of membrane cofactor protein of complement. Biochem. J. 264, 581.
Gordon D. L., Kaufman R. M., Blackmore T. K., Kwong J., and Lublin D. M. (1995) Identification of complement regulatory domains in human factor H. J.Immunol. 155, 348.
Seya T., Nakamura K., Masaki T., C. Ichihara-Itoh, Matsumoto M., and Nagasawa S. (1995) Human factor H and C4b-binding protein serve as factor I-cofactors both encompassing inactivation of C3b and C4b. Molec. Immunol. 32, 355.
Adams E. M., Brown M. C., Nunge M., Krych M., and Atkinson J. P.(1991) Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J.Immunol. 147, 3005.
van den Berg C. W., J. M. Perez de la Lastra, Llanes D., and Morgan B. P. (1997) Purification and characterization of the pig analogue of human membrane cofactor protein (CD46/MCP). J. Immunol. 158, 1703.
Tsujimura A., Shida K., Kitamura M., Nomura M., Takeda J., Tanaka H., Matsumoto M., et al. (1998) Molecular cloning of a murine homologue of membrane cofactor protein (CD46): Preferential expression in testicular germ cells. Biochem. J. 330, 163.
Seya T., Hara T., Iwata K., Kuriyama S., Hasegawa T., Nagase Y., et al. (1995) Purification and functional properties of soluble forms of membrane cofactor protein (CD46) of complement: identification of forms increased in cancer patients′sera. Int. Immunol. 7, 727.
Lachmann P. J. and Thompson R. A. (1970) Reactive lysis: the complement mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J. Experiment. Med. 131, 643.
Thompson R. A. and Lachmann P. J. (1970) Reactive lysis: the complement mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J. Experiment. Med. 131, 629.
Whitlow M. B., Iida K., Stefanova I., Bernard A., and Nussenzweig V. (1990) H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement. Cell. Immunol. 126, 176.
van den Berg C. W. and Morgan B. P. (1994) Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted. J. Immunol. 152, 4095.
Bokisch V. A., Muller-Eberhard H. J., and Cochrane C. G. (1969) Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J. Experiment. Med. 129, 1109.
Avery V. M. and Gordon D. L. (1993) Characterization of factor H binding to human polymorphonuclear leukocytes. J. Immunol. 151, 5545.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Harris, C.L. (2000). Functional Assays for Complement Regulators. In: Morgan, B.P. (eds) Complement Methods and Protocols. Methods in Molecular Biology, vol 150. Humana Press. https://doi.org/10.1385/1-59259-056-X:83
Download citation
DOI: https://doi.org/10.1385/1-59259-056-X:83
Publisher Name: Humana Press
Print ISBN: 978-0-89603-654-3
Online ISBN: 978-1-59259-056-8
eBook Packages: Springer Protocols